Edition:
United States

ARIAD Pharmaceuticals Inc (ARIA.OQ)

ARIA.OQ on NASDAQ Stock Exchange Global Select Market

8.21USD
27 May 2016
Change (% chg)

$0.18 (+2.24%)
Prev Close
$8.03
Open
$8.06
Day's High
$8.21
Day's Low
$7.98
Volume
625,826
Avg. Vol
914,947
52-wk High
$10.06
52-wk Low
$4.38

ARIA.OQ

Chart for ARIA.OQ

About

ARIAD Pharmaceuticals, Inc. (ARIAD) is an oncology company. The Company is focused on transforming the lives of cancer patients with medicines. The Company's product pipeline includes Iclusig (ponatinib), brigatinib, AP32788 and ridaforolimus. The Company's Iclusig is a tyrosine kinase inhibitor (TKI) that is approved in the... (more)

Overall

Beta: 1.73
Market Cap(Mil.): $1,570.01
Shares Outstanding(Mil.): 191.23
Dividend: --
Yield (%): --

Financials

  ARIA.OQ Industry Sector
P/E (TTM): -- 44.29 35.58
EPS (TTM): -1.23 -- --
ROI: -53.26 -5.26 13.32
ROE: -- -5.09 14.59

BRIEF-Ariad Pharmaceuticals announces pricing, reimbursement for iclusig in France

* Ariad announces pricing and reimbursement for iclusig in France

May 19 2016

BRIEF-Ariad Pharmaceuticals posts Q1 loss per share $0.28

* Ariad reports first quarter 2016 financial results and progress on strategic review

May 10 2016

BRIEF-Ariad Pharmaceuticals says board approved increase in size of board to eleven directors

* Effective as of May 4, 2016, board approved an increase in size of board from nine to eleven directors - sec filing

May 06 2016

U.S. activist investors finding fewer opportunities; compromise more common

By Svea Herbst-Bayliss, Lawrence Delevingne and Michael Flaherty

Apr 19 2016

U.S. activist investors finding fewer opportunities; compromise more common

By Svea Herbst-Bayliss, Lawrence Delevingne and Michael Flaherty

Apr 19 2016

BRIEF-Ariad presents updated Phase 1/2 clinical data on brigatinib

* Ariad presents updated Phase 1/2 clinical data on brigatinib in patients with alk+ non-small cell lung cancer

Apr 15 2016

BRIEF-Ariad Pharmaceuticals estimates recording $3.3 mln charge related to termination benefits

* As a result of workforce reduction, estimates recording a one-time charge of about $3.3 million related to termination benefits

Mar 29 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : Stock Traders Daily
$20.00
Provider : New Constructs, LLC
$25.00
Provider : Thomson Reuters Stock Report
$25.00
Provider : ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.